Mazdutide vs DSIP
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
- Half-Life
- ~7 days
- ~30–60 minutes; however downstream sleep effects last 4–6 hours
- Admin Route
- SubQ
- SubQ, IV, Intranasal
- Research
- —
- —
- Typical Dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- 100–400 mcg
- Frequency
- Once weekly
- Once nightly
- Key Benefits
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Induces and deepens delta-wave (slow-wave) sleep
- Reduces cortisol and normalizes HPA axis
- Improves sleep quality in insomnia patients
- Anti-stress and anxiolytic effects
- May improve opiate/alcohol withdrawal symptoms
- Analgesic properties through opioid modulation
- Antioxidant and neuroprotective effects
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Generally well tolerated
- Mild grogginess next morning at higher doses
- Rare: hypotension
- Potential for altered dream patterns
- Stacks With
- —
- —